Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials

M Peeters,E. Van Cutsem,Jordan Berlin,J.R. Hecht,R. Ruiz,Lynn Navale,R Amado,N. J. Meropol

Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials

2007

M Peeters
E. Van Cutsem
Jordan Berlin
J.R. Hecht
R. Ruiz
Lynn Navale
R Amado
N. J. Meropol

4138 Background: Panitumumab is indicated in pts with EGFr-expressing mCRC refractory to chemotherapy. We present a summary of safety with panitumumab monotherapy in mCRC pts across 10 clinical tri...

Keywords:

Clinical trial
Immunology
Epidermal growth factor receptor
Colorectal cancer
Monoclonal antibody
Medicine
Panitumumab
Oncology
Chemotherapy
Refractory
Internal medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations